Rome Therapeutics
Executivos
Veja o organograma con seus 17 executivos principais
Biografias mais buscadas da Rome Therapeutics
- Rosana Kapeller, President, Chief Executive Officer and Director
- Jeff Hatfield, Chairman of the Board
- Steven Kafka, Director
Recentes movimentos de executivos em Rome Therapeutics
- Heike Keilhack, ingressou na Companhia como Chief Scientific Officer (Notícia publicada em 5 de janeiro de 2024).
- Kyle Kuvalanka, ingressou na Companhia como Chief Financial Officer and Chief Business Officer (Notícia publicada em 5 de outubro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Rome Therapeutics.
Biotecnologia
Rome Therapeutics possui 2.288 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Attovia Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 14 de maio de 2024).
- Bruker has announced the acquisition of NanoString Technologies (publicado em 13 de maio de 2024).
- Aardvark Therapeutics acaba de anunciar uma arrecadação de fundos de 85 milhões de dólares. (publicado em 12 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Rome Therapeutics
- ROME Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference – ROME Therapeutics
- ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer – ROME Therapeutics
- ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery – ROME Therapeutics
- ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors – ROME Therapeutics
- Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium – ROME Therapeutics
- ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer – ROME Therapeutics
- ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease – ROME Therapeutics
- ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development – ROME Therapeutics
- ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease – ROME Therapeutics
- ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research – ROME Therapeutics
- View more press releases Close
Redes sociais sobre Rome Therapeutics
- Rome Therapeutics na Wikipedia, Google News e Yahoo Finance
- Rome Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Rosana Kapeller 
Ligue para a Rome Therapeutics em +1 617...
